Varenicline Tablet, Film Coated
Product Images NDC 60505-3613

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 60505-3613). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Btl-28-0.5.jpg (Btl 28 0.5)

Label for Varenicline Tablets 0.5 mg by Apotex Corp, containing 28 film-coated tablets. The label states each tablet contains 0.5 mg varenicline free base. Storage instructions and dispensing notes for pharmacists are included, along with the manufacturer addresses in Toronto, Ontario, and Weston, Florida. The product is identified by NDC 60505-3613-2.*

FDA Label Image

Btl-28-1.jpg (Btl 28 1)

Label for Varenicline Tablets 1 mg, film-coated oral tablets. The package contains 28 tablets. The label includes storage instructions, dosing note to see package insert, and highlights that it is a prescription drug. Manufactured by Apotex Corp in Canada and Florida. Barcode and NDC 60505-3614-2 are visible.*

FDA Label Image

Bottle-label-0pt5mg (Lbl0.5mg56s)

Label for Varenicline Tablets 0.5 mg film-coated tablets by Apotex Corp. The package contains 56 tablets with NDC 60505-3613-5. The label includes storage instructions, dosage strength, pharmacist dispensing instructions, and manufacturer information from Apotex Inc., Canada and Apotex Corp., Florida.*

FDA Label Image

Bottle-lable-1mg (Lbl1mg56s)

Varenicline Tablets 1 mg film-coated oral tablets in a package of 56 tablets. The label indicates each tablet contains 1 mg varenicline free base. Manufactured by Apotex Inc., Canada, and distributed by Apotex Corp. Storage instructions and pharmacist dispensing guidance are included on the label.*

FDA Label Image

Figure-1 (Figure 1)

A bar graph titled 'Continuous Abstinence, Weeks 9 through 12' comparing percentages across five studies. It shows the continuous abstinence rates for different doses and forms of Varenicline, Bupropion sustained release, and placebo, with each category having vertical bars and error bars indicating variability.*

FDA Label Image

Figure-2 (Figure 2)

A bar graph titled 'Continuous Abstinence, Weeks 9 through 52' showing comparative percentages of continuous abstinence rates across five studies. The x-axis lists different treatments including Varenicline 0.5 mg BID, Varenicline 1.0 mg BID, Varenicline Flexible, Bupropion SR 150 mg BID, and Placebo. The y-axis indicates the percentage scale from 0% to 35%. Bars represent the abstinence rates with error bars for variability in each category.*

FDA Label Image

Figure-3 (Figure 3)

Line graph depicting the percentage of continuous abstinent subjects over nontreatment follow-up weeks comparing Varenicline 1.0 mg twice daily to placebo. The graph shows a decline in abstinence percentage over time for both treatments, with Varenicline maintaining a higher rate than placebo throughout the follow-up period.*

FDA Label Image

Structure-1 (Structure 1)

Chemical structure of varenicline, showing its molecular framework with distinct ring systems and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.